Page 2 - தேசிய நிறுவனம் க்கு வைரஸ் நோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Nation s rapid response gives vaccine makers head start
chinadaily.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chinadaily.com.cn Daily Mail and Mail on Sunday newspapers.
Nation s rapid response gives vaccine makers head start
chinadaily.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chinadaily.com.cn Daily Mail and Mail on Sunday newspapers.
Nation s rapid response led to vaccine miracle By WANG XIAODONG | China Daily Global | Updated: 2021-02-22 09:58 Share CLOSE A cargo container of COVID-19 vaccine is unloaded at the airport in Mexico City, Mexico, on Saturday as Mexico received its first shipment of vaccines made by Chinese company Sinovac. XIN YUEWEI/XINHUA
When Wu Guizhen and her colleagues at the Chinese Center for Disease Control and Prevention in Beijing received their first sample of an unknown virus on Jan 2,2020, they immediately rushed to identify it.
The sample had been collected from a pneumonia patient in Wuhan, Hubei province. It s similar to when you cannot see the enemy during a war if you cannot get a clear picture of a virus when fighting an infectious disease, said Wu, chief biosafety expert at the China CDC.
Nation s rapid response led to vaccine miracle
chinadaily.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chinadaily.com.cn Daily Mail and Mail on Sunday newspapers.
Published February 6, 2021, 10:30 AM
BEIJING More than 31 million doses of COVID-19 vaccine had been administered in China as of Feb. 3, according to China’s National Health Commission.
Preliminary tests showed that the incidence of severe abnormal reactions caused by the COVID-19 vaccines currently used in China is no higher than that of the influenza vaccine, said Xu Wenbo, head of the National Institute for Viral Disease Control and Prevention under the Chinese Center for Disease Control and Prevention.
In late December 2020, an inactivated vaccine developed by Beijing Biological Products Institute Co., Ltd. under the China National Biotec Group (CNBG), affiliated with Sinopharm, became the first to receive conditional market approval from the National Medical Products Administration.